Merck Quick Ratio 2010-2024 | MRK

Historical quick ratio values for Merck (MRK) over the last 10 years.
Merck Quick Ratio Historical Data
Date Current Assets - Inventory Current Liabilities Quick Ratio
2024-12-31 $32.67B $28.42B 1.15
2024-09-30 $34.12B $29.59B 1.15
2024-06-30 $31.74B $26.06B 1.22
2024-03-31 $24.94B $25.10B 0.99
2023-12-31 $25.81B $25.69B 1.01
2023-09-30 $25.82B $23.09B 1.12
2023-06-30 $24.05B $23.39B 1.03
2023-03-31 $27.54B $23.13B 1.19
2022-12-31 $29.81B $24.24B 1.23
2022-09-30 $27.95B $23.00B 1.22
2022-06-30 $26.58B $23.17B 1.15
2022-03-31 $25.41B $22.32B 1.14
2021-12-31 $24.31B $23.87B 1.02
2021-09-30 $25.46B $23.73B 1.07
2021-06-30 $23.17B $21.91B 1.06
2021-03-31 $20.51B $26.36B 0.78
2020-12-31 $22.21B $27.33B 0.81
2020-09-30 $20.45B $20.41B 1.00
2020-06-30 $23.29B $22.18B 1.05
2020-03-31 $20.33B $23.48B 0.87
2019-12-31 $21.51B $22.22B 0.97
2019-09-30 $20.29B $20.68B 0.98
2019-06-30 $18.45B $20.09B 0.92
2019-03-31 $19.64B $18.54B 1.06
2018-12-31 $20.44B $22.21B 0.92
2018-09-30 $21.42B $18.59B 1.15
2018-06-30 $18.89B $18.13B 1.04
2018-03-31 $18.70B $16.96B 1.10
2017-12-31 $19.67B $18.61B 1.06
2017-09-30 $22.66B $19.47B 1.16
2017-06-30 $22.76B $18.76B 1.21
2017-03-31 $26.38B $19.82B 1.33
2016-12-31 $25.75B $17.20B 1.50
2016-09-30 $24.20B $15.56B 1.56
2016-06-30 $22.68B $14.92B 1.52
2016-03-31 $23.67B $17.57B 1.35
2015-12-31 $25.05B $19.20B 1.31
2015-09-30 $23.44B $17.58B 1.33
2015-06-30 $23.01B $17.51B 1.31
2015-03-31 $27.39B $20.44B 1.34
2014-12-31 $27.03B $18.40B 1.47
2014-09-30 $28.90B $25.93B 1.12
2014-06-30 $27.45B $17.93B 1.53
2014-03-31 $34.86B $22.47B 1.55
2013-12-31 $29.46B $17.87B 1.65
2013-09-30 $31.02B $18.22B 1.70
2013-06-30 $30.23B $18.40B 1.64
2013-03-31 $28.47B $18.80B 1.51
2012-12-31 $28.32B $18.35B 1.54
2012-09-30 $29.50B $15.58B 1.89
2012-06-30 $29.39B $16.91B 1.74
2012-03-31 $28.01B $16.58B 1.69
2011-12-31 $26.93B $16.25B 1.66
2011-09-30 $27.87B $16.59B 1.68
2011-06-30 $26.14B $15.76B 1.66
2011-03-31 $24.97B $15.66B 1.59
2010-12-31 $23.20B $15.64B 1.48
2010-09-30 $21.49B $17.32B 1.24
2010-06-30 $20.01B $15.42B 1.30
2010-03-31 $21.42B $16.46B 1.30
2009-12-31 $20.38B $15.64B 1.30
2009-09-30 $27.57B $8.03B 3.44
2009-06-30 $27.08B $11.51B 2.35
2009-03-31 $24.06B $13.42B 1.79
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $226.737B $64.168B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $783.103B 63.53
Johnson & Johnson (JNJ) United States $399.649B 16.60
AbbVie (ABBV) United States $370.636B 20.70
Novo Nordisk (NVO) Denmark $311.614B 21.11
Roche Holding AG (RHHBY) Switzerland $262.452B 0.00
Novartis AG (NVS) Switzerland $227.865B 14.27
Pfizer (PFE) United States $143.715B 8.15
Sanofi (SNY) $140.749B 13.33
Bayer (BAYRY) Germany $23.657B 4.39
Innoviva (INVA) United States $1.136B 10.48